VRTX Vertex Pharmaceuticals
- 495.260
- +3.000+0.61%
- 495.000
- -0.260-0.05%
Vertex Pharmaceuticals News
Needham Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $500 From $450, Maintains Buy Rating
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Strategic Acquisition and Strong CF Franchise Outlook
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $480 From $440
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500
Vertex Pharmaceuticals Analyst Ratings
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating
Vertex Pharmaceuticals Analyst Ratings
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402
Vertex Pharmaceuticals Analyst Ratings
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating
Vertex Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
